Back to Search
Start Over
Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma.
- Source :
-
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2007 Sep 20; Vol. 25 (27), pp. 4293-7. Date of Electronic Publication: 2007 Aug 20. - Publication Year :
- 2007
-
Abstract
- Purpose: To determine the antitumor activity of the proteasome inhibitor bortezomib in patients with cutaneous T-cell lymphoma (CTCL) or peripheral T-cell lymphoma unspecified (PTCLU) with isolated skin involvement.<br />Patients and Methods: From May 2005 to June 2006 at our institute, we treated patients with previously pretreated CTCL or PTCLU using bortezomib as a single agent, at a dose of 1.3 mg/m2 intravenously on days 1, 4, 8, and 11, every 21 days for a total of six cycles.<br />Results: Fifteen patients were registered, of whom 12 (10 CTCL, all mycosis fungoides, and two PTCLU with isolated skin involvement) were assessable. The overall response rate was 67%, with two (17%) complete remissions and six (50%) partial remissions. The remaining four patients had disease progression. Histologically, the responder patients were seven with CTCL and one with PTCLU with isolated skin involvement. All responses were durable, lasting from 7 to 14 or more months. Overall, the drug was well tolerated, with no grade 4 toxicity. The most common grade 3 toxicities were neutropenia (n = 2), thrombocytopenia (n = 2), and sensory neuropathy (n = 2).<br />Conclusion: This study suggests that bortezomib was well tolerated and has significant single-agent activity in patients with cutaneous T-cell lymphoma.
- Subjects :
- Aged
Aged, 80 and over
Bortezomib
Female
Humans
Lymphoma, T-Cell pathology
Male
Middle Aged
Mycosis Fungoides pathology
Recurrence
Remission Induction
Skin Neoplasms pathology
Treatment Outcome
Antineoplastic Agents administration & dosage
Boronic Acids administration & dosage
Lymphoma, T-Cell drug therapy
Mycosis Fungoides drug therapy
Protease Inhibitors pharmacology
Pyrazines administration & dosage
Skin Neoplasms drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1527-7755
- Volume :
- 25
- Issue :
- 27
- Database :
- MEDLINE
- Journal :
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 17709797
- Full Text :
- https://doi.org/10.1200/JCO.2007.11.4207